e-ISSN: 2394-2967
logo

British Journal of Medical and Health Research

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

Volume 9, Issue 4 - 2022 (April 2022 Issue 4)

Volume 9 Issue 4 Cover

Issue Details:

Volume 9 Issue 4
Published:Invalid Date

Editorial: April 2022 Issue 4

Welcome to the 2022 issue of British Journal of Medical and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr Hemangi J Patel
Editor-in-Chief
British Journal of Medical and Health Research

Articles in This Issue

Showing 2 of 2 articles
Research PaperID: BJMHR0904001

Various Synthetic Pathways of Flavanones Focused on their Biological Activity: A Review

Somashekhar Metri, Basavraj Dashyal, Sammed Melvanki, Maharani B, Md Iliyas, R B Kotnal

ABSTRACT Flavanones are a diverse group of phytonutrients found in most plants. They act as pigments, producing many colours like yellow, red and orange found in plant-based diets. Flavanones have become an essential component in a wide range of nutraceutical, pharmacological, therapeutic, and cosmetic applications. This is due to their ability to control critical cellular enzyme activity as well as their anti-inflammatory, Flavanones were discovered in 1938 by a Hungarian scientist named Dr. Albert Szent-Gyorgyi, who identified them as vitamin P. The challenge is that the chemistry of Flavanones is difficult because there are over 6,000 distinct compounds that belong to the flavonoid family. These challenges could be overcome by optimization techniques, novel technology, fermentation and metabolic engineering. The functional recommendations that could be added here are population heterogeneity, high study cost and time. Many different chemical families of compounds such as Flavonols, dihydroflavonols, flavones, isoflavones, flavanones, anthocyanins, and anthocyanidins are among these groups. Hundreds, if not thousands, of distinct Flavanones can be found in each of these families. Examples of some well-known flavonols include quercetin, rutin, and hesperidin while well-known apigenin and luteolin. Keywords: Flavanones, Antimicrobial activity, Anticancer activity, Bio Flavanones, Antibacterial characteristics.

FlavanonesAntimicrobial activityAnticancer activityBio FlavanonesAntibacterial characteristics.
50,967 views
15,270 downloads

Contributors:

 Somashekhar Metri
,
 Basavraj Dashyal
,
 Sammed Melvanki
,
 Maharani B
,
 Md Iliyas
,
 R B Kotnal
Research PaperID: BJMHR0904002

Acromegaly in Young

Kshitij Sanjay Kumat, Dharmendra Janardanrai Vatsaraj, Siddharth Kaushik Shah, Deepali Vijay Lodha

Acromegaly is a rare,slowly progressive disease caused by chronic hypersecretion of growth hormone (GH) and excess circulating insulin-like growth factor-1 (IGF-1). The etiology of acromegaly is almost invariably an underlying GH-secreting pituitary adenoma. Rarely, it is due to a hypothalamic tumor secreting GHRH or ectopic growth hormone releasing hormone (GHRH) secretion, or very rarely GH from an ectopic source. We are here reporting a case of 21 yrs old female who presented with headache and amenorrhea since 1 year which on investigating patient had Acromegaly due to Pituitary Adenoma. Therapy for Acromegaly is targeted at decreasing GH and IGF-1 levels, ameliorating patients symptoms and decreasing any local compressive effects of the pituitary adenoma. The therapeutic options for acromegaly include surgery, medical therapies(dopamine agonists, somatostatin receptor agonists and the GH receptor antagonist) and radiotherapy. A multi disciplinary approach is recommended with often a requirement for combined treatment modalities. With disease control, associated morbidity and mortality can be reduced

Acromegaly in YoungPituitary Adenoma
50,949 views
15,354 downloads

Contributors:

 Kshitij Sanjay Kumat
,
 Dharmendra Janardanrai Vatsaraj
,
 Siddharth Kaushik Shah
,
 Deepali Vijay Lodha